Raman-based metabonomics unravels metabolic changes related to a first-line tenofovir-based treatment in a small cohort of South African HIV-infected patients

In addition to immunological disorders, human immunodeficiency virus (HIV) also causes metabolic abnormalities. Though successful in viral suppression and immune restoration, continued use of antiretroviral therapy (ART) has also been linked to the development of several metabolic ailments. Currently, the only clinical markers used to manage and monitor the development of HIV-induced metabolic disorders, disease progression as well as observing individual's response to antiviral treatment are CD4 count, viral loads and several other single variable colometric assays. Despite the common use of these clinical markers, these markers remain unreliable and limited in the ability to monitor the development of metabolic disorders as well as monitor treatment response. Given these limitations, it is imperative to discover and develop reliable biological markers for overall HIV disease management. Here, Raman spectroscopy was used to profile metabolic changes in the plasma of 22 HIV' receiving a first-line tenofovir-based combination antiretroviral therapy compared to their 8 HIV' ARTand 10 HIVcounterparts. Multivariate statistical analysis was performed in order to classify the samples into their respective groups and to identify significantly altered metabolites between the control and experimental groups. Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) discriminant analysis identified significant differences (p < 0.05) in 9 different metabolites. Alterations were identified in spectral regions associated with glucose (1124 cm(-1)), lipids/phospholipids (1116 cm(-1), 1098 cm(-1), 1077 cm(-1)), proteins (1120 cm(-1)), nucleic acids (1081 cm(-1)) and phenylalanine (1103 cm(-1)). Pathway analysis also revealed 3 significantly altered pathways. This study presented the reproducible nature of Raman spectroscopy in distinguishing between HIV-infected (treated and untreated) and uninfected blood plasma and allowed for the detection and identification of treatment induced metabolite changes. The results obtained in the study may, therefore, give insights into understanding the metabolic effect of HIV therapy. (C) 2020 Elsevier B.V. All rights reserved.

Automated summary

HIV infection can lead to metabolic disorders, with current clinical markers being limited and unreliable. This study used Raman spectroscopy to analyze metabolic changes in plasma of different HIV treatment groups and controls, identifying significant differences and altered metabolites. The study highlights the potential of Raman spectroscopy in distinguishing metabolic effects of HIV therapy.